Loading investment pitches...
Equity Research Database
Institutional Investment Pitches
Explore thousands of hedge fund pitches, high-conviction equity research memos, and portfolio manager commentary extracted from quarterly letters.
Explore thousands of hedge fund pitches, high-conviction equity research memos, and portfolio manager commentary extracted from quarterly letters.
Explore professional investment ideas sourced from institutional letters, short theses, and premium research channels, distilled into concise summaries.
| Pitch Type | Author | Industry | Pitch Thesis & Key Summary | Bull/Bear | Action | ||
|---|---|---|---|---|---|---|---|
| Sep 2, 2026 | Fund Letter | Richard OldfieldOldfield Partners Overstone World All Cap Equity Fund | PharmaceuticalsPharmaceuticals | Oldfield Partners Overstone World All Cap Equity Fund - SNY Sanofi was a detractor this quarter. A run of... | NEUTRAL | View Pitch → | |
| Aug 21, 2026 | Fund Letter | David G. Herro, Tony Coniaris, Eric Liu, M. Colin Hudson, John A. SitarzOakmark Global Select Fund | PharmaceuticalsPharmaceuticals | Long SNY (Sanofi) Sanofi's strong fundamentals and core asset Dupixent are undervalued due to temporary vaccine market volatility and patent cliff anxieties. The manager bought... | BULL | View Pitch → | |
| Aug 21, 2026 | Fund Letter | Ariel Investments, LLCAriel International Fund | PharmaceuticalsPharmaceuticals | Long SNY (Sanofi) Market concerns over a potential vaccine critic heading the US HHS caused an industry-wide sell-off, which the manager believes is an overreaction for Sanofi given its vaccine division's small revenue share. The pipeline for... | BULL | View Pitch → | |
| Aug 21, 2026 | Fund Letter | Oldfield Partners Overstone Global Large Cap | PharmaceuticalsPharmaceuticals | Long SNY (Sanofi) Sanofi was a detractor this quarter. | BULL | View Pitch → | |
| Feb 20, 2026 | Fund Letter | Javier Ruiz, CFAHoros Asset Management | Broadline RetailBroadline Retail | Horos Asset Management 2025 Q4 (NPSNY) In the case of Naspers, our investment has gone through two periods of significant challenges during the years we have held the company. The first took... | BULL | View Pitch → |
Join institutional and professional investors receiving our weekly analysis of hedge fund letters, market trends, and high-conviction ideas.
Zero Spam • High Alpha • Unsubscribe Anytime
Investment pitches and theses displayed on Buyside Digest are summaries of opinions expressed in publicly available investor letters, research reports, or other commentary. These summaries are generated for informational and research purposes only and do not constitute investment recommendations, financial advice, or an endorsement of any particular security or strategy by Buyside Digest. Users should conduct their own independent due diligence and consult with professional advisors before making any investment decisions.